Less-invasive and highly effective method for preventing methicillin-resistant Staphylococcus aureus graft infection by local sustained release of vancomycin.

[1]  H. Çıralık,et al.  Gelatin-sealed dacron graft is not more susceptible to MRSA infection than PTFE graft. , 2006, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[2]  Y. Tabata,et al.  Sustained-release vancomycin sheet may help to prevent prosthetic graft methicillin-resistant Staphylococcus aureus infection. , 2006, Journal of vascular surgery.

[3]  J. Shah,et al.  Local Delivery of Vancomycin for the Prophylaxis of Prosthetic Device-Related Infections , 2005, Pharmaceutical Research.

[4]  M Fini,et al.  New polymers for drug delivery systems in orthopaedics: in vivo biocompatibility evaluation. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  C. Gabka,et al.  Rifampin and Triclosan but not silver is effective in preventing bacterial infection of vascular dacron graft material. , 2003, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[6]  N. Azuma,et al.  Limitations in the use of rifampicin-gelatin grafts against virulent organisms. , 2002, Journal of vascular surgery.

[7]  A Odero,et al.  Vascular prosthetic Graft Infection: Epidemiology, Bacteriology, Pathogenesis and Treatment , 2002, Acta chirurgica Belgica.

[8]  A. Naylor,et al.  The impact of MRSA on vascular surgery. , 2001, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[9]  R. Pararajasingam,et al.  Methicillin-resistant Staphylococcus aureus infection in vascular surgical patients. , 2001, Annals of the Royal College of Surgeons of England.

[10]  L. Goffi,et al.  Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. , 2000, The Journal of antimicrobial chemotherapy.

[11]  T. Huber,et al.  Long-term outcome after treatment of aortic graft infection with staged extra-anatomic bypass grafting and aortic graft removal. , 2000, Journal of vascular surgery.

[12]  K. Calligaro.  Regarding "in situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience (1992 to 1998)". , 2000, Journal of vascular surgery.

[13]  J. Hallett,et al.  The results of in situ prosthetic replacement for infected aortic grafts. , 1999, American journal of surgery.

[14]  R. Sayers,et al.  In situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience (1992 to 1998) , 1999 .

[15]  M. Ando,et al.  A new method for the treatment of graft infection in the thoracic aorta: in situ preservation. , 1999, The Annals of thoracic surgery.

[16]  J. Earnshaw,et al.  Mechanism of late prosthetic vascular graft infection. , 1997, Cardiovascular surgery.

[17]  T. Nabeshima,et al.  Subcutaneous tissue distribution of vancomycin from a fibrin glue/Dacron graft carrier. , 1997, Journal of biomedical materials research.

[18]  Gomes Mn,et al.  Pedicled muscle flaps in the management of infected aortofemoral grafts. , 1994 .

[19]  J. Ricotta,et al.  Total excision and extra-anatomic bypass for aortic graft infection. , 1991, American journal of surgery.

[20]  B. Ratner,et al.  Protein bonding on biodegradable poly(L-lactide-co-caprolactone) membrane for esophageal tissue engineering. , 2006, Biomaterials.

[21]  S. Wilson,et al.  Local treatment of prosthetic vascular graft infection with multivesicular liposome-encapsulated amikacin. , 1998, The Journal of surgical research.

[22]  J. Richardson,et al.  Current options in prosthetic vascular graft infection. , 1998, The American surgeon.